GET DAILY SIGNALSPhilips (PHG) Delivers Steady Q3 Growth With Margin Expansion
Key Takeaways
- Comparable sales rose 3% to €4.39 billion, led by Personal Health (+8%) and Connected Care (+5%), while Diagnosis & Treatment was flat.
- Adjusted EBITA climbed to €569 million, lifting the adjusted EBITA margin 70 basis points to 13.0%.
- Comparable order intake grew 8%, driven by an approaching-20% increase in Diagnosis & Treatment orders.
- Net income fell to €28 million from €187 million a year earlier, largely due to a €288 million provision tied to the Respironics agreement in principle with the U.S. Department of Justice.
- Philips reiterated its full-year 2026 outlook for 3%–4.5% comparable sales growth and an adjusted EBITA margin of 13.5%–14.0%.
Earnings Context and Why It Matters
Koninklijke Philips N.V. reported its third-quarter 2026 results on November 3, 2026. The update provides a timely check on whether the Dutch health technology company is sustaining its recovery after the prolonged Respironics recall challenges. Philips has focused on margin improvement, productivity gains, and AI-driven product development to restore investor confidence. This quarter is particularly relevant as it shows whether rising order intake is translating into sales, whether profitability improvements are holding up, and how the company is managing lingering legal issues. With guidance reaffirmed, the results give a clear signal on execution as the year wraps up.
Reported Results
Comparable sales increased 3% to €4.39 billion, supported by mid-single-digit growth in Connected Care and high-single-digit growth in Personal Health. Adjusted EBITA rose to €569 million from €531 million, with the margin expanding 70 basis points to 13.0% across all segments. Comparable order intake advanced 8%, fueled by nearly 20% growth in Diagnosis & Treatment orders. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported net income declined to €28 million from €187 million, mainly because of a €288 million provision related to the agreement in principle with the U.S. Department of Justice on the Respironics matter. Adjusted earnings per share reached €0.40, up from €0.36 and ahead of consensus. Free cash flow improved to €384 million from €172 million in the prior-year quarter.
Market Reaction and Investor Sentiment
Shares of PHG rose about 3% to €25.31 in Amsterdam trading, hitting their highest level since early March, while U.S.-listed ADRs moved higher in premarket. Investors focused on the stronger adjusted earnings and order trends rather than the anticipated legal provision. Analysts viewed the quarter as mixed, with solid adjusted EBITA and Connected Care performance offset by softer Diagnosis & Treatment sales due to ultrasound shipment timing and weaker China demand. The positive market response indicates that progress on margins and orders is being rewarded even as revenue acceleration questions remain.
Forward Outlook and Key Factors to Monitor
Philips kept its full-year 2026 guidance unchanged, expecting comparable sales growth of 3% to 4.5%, an adjusted EBITA margin of 13.5% to 14.0%, and free cash flow between €1.5 billion and €1.7 billion. The margin target includes roughly 1% benefit from U.S. tariff refunds. Management noted that ultrasound sales delayed by manufacturing improvements should appear in the fourth quarter and early 2027, supporting faster growth in Diagnosis & Treatment.
Several items warrant attention in upcoming quarters. The final Respironics DOJ settlement, expected in the first quarter of 2027, may influence near-term cash flow, while other related proceedings continue. China’s centralized procurement expansions and softer consumer demand add uncertainty to Diagnosis & Treatment and Personal Health. The company’s success in turning its expanding order book into revenue, especially in precision diagnosis and image-guided therapy, will be essential for reaching medium-term targets of mid-single-digit sales growth and a mid-teen adjusted EBITDA margin by 2028. Cost pressures, tariff effects, and the pace of savings from the €1.5 billion three-year productivity program will also influence margins. As new AI-enabled platforms roll out, traction for products like the Spectral CT portfolio and helium-free MR systems will help gauge the sustainability of growth.
Using Tickeron AI Tools for Deeper Analysis
In my research on names like PHG, I often turn to Tickeron’s AI-powered tools to quickly scan for comparable companies and technical setups. These resources help streamline the process of identifying relevant peers and spotting potential patterns across the medical technology sector without spending hours on manual screening. From what I see, they provide a practical starting point when evaluating how a stock stacks up against industry benchmarks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PHG in upward trend: price rose above 50-day moving average on October 20, 2026
PHG moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on PHG as a result. In 51 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for PHG just turned positive on October 08, 2026. Looking at past instances where PHG's MACD turned positive, the stock continued to rise in 25 of 48 cases over the following month. The odds of a continued upward trend are 52%.
The 10-day moving average for PHG crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +5.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHG advanced for three days, in 205 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 109 of 201 cases where PHG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
PHG broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.356) is normal, around the industry mean (4.170). P/E Ratio (23.581) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.768) is also within normal values, averaging (11.253). PHG's Dividend Yield (0.147) is considerably higher than the industry average of (0.010). P/S Ratio (1.175) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. PHG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a diversified technology company, engages in providing healthcare, consumer lifestyle and lighting services
Industry MedicalNursingServices
Advertisement